Esperion Therapeutics, Inc. is a biopharmaceutical company based in Ann Arbor, Michigan, focused on developing innovative therapies to significantly reduce elevated low-density lipoprotein cholesterol (LDL-C). The firm aims to transform cardiovascular disease treatment through its advanced lipid-lowering agents, addressing a critical unmet need in dyslipidemia management. With a robust pipeline and a commitment to patient-centered care, Esperion is strategically positioned to enhance patient outcomes and drive advancements in cardiovascular health. As the company progresses, it stands to substantially influence the future of lipid management therapies in the healthcare landscape. Show more

Location: 3891 RANCHERO DRIVE, ANN ARBOR, MI, UNITED STATES, 48108, Ann Arbor, MI, 48108, USA | Website: https://www.esperion.com | Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC | Sector: HEALTHCARE

Market Cap

810.4M

52 Wk Range

$0.69 - $4.17

Previous Close

$3.55

Open

$3.51

Volume

4,176,144

Day Range

$3.35 - $3.60

Enterprise Value

1.022B

Cash

92.45M

Avg Qtr Burn

-4.286M

Insider Ownership

0.61%

Institutional Own.

48.09%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Nexlizet (bempedoic acid and ezetimibe) Details Hypercholesterolemia, Atherosclerotic cardiovascular disease , Heterozygous familial hypercholesterolemia, Cardiovascular risk reduction	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nexletol (bempedoic acid) Details Heterozygous familial hypercholesterolemia, Atherosclerotic cardiovascular disease , Hypercholesterolemia	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bempedoic acid Details Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ESP-2001 (ACLY Inhibitor) Details Primary Sclerosing Cholangitis	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.